1. Home
  2. UNP vs VRTX Comparison

UNP vs VRTX Comparison

Compare UNP & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Union Pacific Corporation

UNP

Union Pacific Corporation

HOLD

Current Price

$232.00

Market Cap

130.7B

Sector

Industrials

ML Signal

HOLD

Logo Vertex Pharmaceuticals Incorporated

VRTX

Vertex Pharmaceuticals Incorporated

HOLD

Current Price

$478.59

Market Cap

115.7B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
UNP
VRTX
Founded
1862
1989
Country
United States
United States
Employees
N/A
N/A
Industry
Railroads
EDP Services
Sector
Industrials
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
130.7B
115.7B
IPO Year
N/A
1991

Fundamental Metrics

Financial Performance
Metric
UNP
VRTX
Price
$232.00
$478.59
Analyst Decision
Buy
Buy
Analyst Count
25
27
Target Price
$259.04
$509.17
AVG Volume (30 Days)
2.7M
1.3M
Earning Date
01-27-2026
02-12-2026
Dividend Yield
2.40%
N/A
EPS Growth
8.28
N/A
EPS
11.78
14.22
Revenue
$24,546,000,000.00
$11,723,300,000.00
Revenue This Year
$2.26
$10.93
Revenue Next Year
$3.52
$8.44
P/E Ratio
$19.49
$32.93
Revenue Growth
1.06
10.33
52 Week Low
$204.66
$362.50
52 Week High
$256.84
$519.68

Technical Indicators

Market Signals
Indicator
UNP
VRTX
Relative Strength Index (RSI) 52.10 62.38
Support Level $219.98 $429.00
Resistance Level $233.68 $472.58
Average True Range (ATR) 4.98 13.74
MACD 0.12 1.07
Stochastic Oscillator 77.21 82.72

Price Performance

Historical Comparison
UNP
VRTX

About UNP Union Pacific Corporation

Omaha, Nebraska-based Union Pacific is the largest public railroad in North America. Operating on more than 30,000 miles of track in the western two-thirds of the US, Union Pacific generated $24 billion of revenue in 2024 by hauling coal, industrial products, intermodal containers, agricultural goods, chemicals, fertilizers, and automotive goods. Union Pacific owns about one-fourth of Mexican railroad Ferromex and historically derives roughly 10% of its revenue hauling freight to and from Mexico.

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Share on Social Networks: